GYREGyre Therapeutics, Inc.
$5.85-26% 1Y
$5.85
$5.5652 weeks$8.76
Is the price fair?
What GYRE's price assumes
Gyre Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 5.56× revenue.
5.56
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 6.14
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 6.14
- EV / EBIToperating margin −14%: the multiple describes the denominator
- not meaningful
- Market capitalisation111.5 million shares, counted Aug 1, 2026
- $652M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.